Related Experiment Video
Updated: Oct 13, 2025
07:05
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
8.4K
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
Ferdinando D'Amico1,2, Fernando Magro3, Laurent Peyrin-Biroulet4
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Journal of Crohn'S & Colitis
|November 18, 2021
Summary
Filgotinib effectively treats moderate to severe ulcerative colitis (UC) with a good safety profile. Further human studies are needed to assess reproductive effects, but the drug shows promise for UC patients.
Area of Science:
- Gastroenterology
- Pharmacology
- Immunology
Background:
- Filgotinib is a selective Janus kinase 1 inhibitor.
- Currently approved for rheumatoid arthritis, it is under investigation for ulcerative colitis (UC).
Purpose of the Study:
- To review current data on filgotinib for UC treatment.
- To determine filgotinib's role in the UC treatment algorithm.
Main Methods:
- Literature search of PubMed, Embase, and Scopus databases up to June 25, 2021.
- Inclusion of studies reporting efficacy and safety data in UC patients.
Main Results:
- Phase III data indicate filgotinib is effective for moderate to severe UC.
- Safety profile is reassuring, with no increased risk of thrombosis or herpes zoster compared to other JAK inhibitors.
- Animal studies suggest potential reproductive effects requiring further human investigation.
Conclusions:
- Filgotinib is an effective and safe option for biologic-naive and biologic-experienced UC patients.
- The drug is anticipated to be available soon for UC treatment.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
267
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
267
01:29Inflammatory Bowel Disease IV: Pharmacological Management
233
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
233
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
01:21Inflammatory Bowel Disease V: Surgical Management
245
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
245